Meeting
2024 ASCO Genitourinary Cancers Symposium
Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.
Authors
Ekamjit Singh Deol
Mayo Clinic Rochester, Rochester, MN
Ekamjit Singh Deol , Cameron J Britton , Jack R. Andrews , Edlira Horjeti , Yohan J Kim , Vidhu B. Joshi , Mohamed E. Ahmed , R. Jeffrey Karnes , Fabrice Lucien
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 334)
DOI
10.1200/JCO.2024.42.4_suppl.334
Abstract #
334
Poster Bd #
P3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Methylated DNA markers in urine aid in the selective identification of patients with prostate cancer as well as clinically significant pathology.
First Author: Paras Shah
Poster
2012 ASCO Annual Meeting
Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2?
First Author: Emma Killick
Poster
2024 ASCO Genitourinary Cancers Symposium
Prostate extracellular vesicles and prediction of clinically significant prostate cancer: A prospective single-institution pilot study.
First Author: Cameron J Britton
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for 177Lu-PSMA therapy in advanced prostate cancer.
First Author: Alin Chirindel